A smarter way to screen for breast cancer is emerging

The groundbreaking findings, published December 12 in JAMA and presented concurrently at the San Antonio Breast Cancer Symposium, are based on comprehensive data from 46,000 women across the United States who participated in the initial phase of the Women Informed to Screen Depending On Measures of Risk (WISDOM) study. This multi-institutional endeavor, with UCSF serving as its coordinating center, points to a major overhaul in how breast cancer screening could be approached, moving decisively away from rigid, age-based rules and toward a dynamic system built around comprehensive, individualized risk evaluation.

The Quest for Personalized Screening: A New Paradigm Emerges

For decades, breast cancer screening guidelines have largely operated under a "one-size-fits-all" model, primarily relying on a woman’s age to dictate the timing and frequency of mammograms. This approach, while effective in reducing mortality rates, has increasingly faced scrutiny due to its inherent limitations: it can lead to overscreening for lower-risk individuals, potentially causing anxiety, unnecessary biopsies, and the detection of indolent cancers (overdiagnosis), while simultaneously underscreening higher-risk women who might benefit from earlier or more frequent surveillance. The WISDOM study directly addresses these concerns, championing a precision medicine approach that promises to enhance the benefits of screening while mitigating its potential harms.

Breast cancer remains an immense public health challenge, standing as the most commonly diagnosed cancer among women in the United States, excluding skin cancers. According to the American Cancer Society, approximately 1 in 8 women will develop invasive breast cancer in their lifetime. While significant strides have been made in treatment, early detection through screening remains a cornerstone of reducing mortality. However, the exact parameters for effective screening have been a subject of ongoing debate among medical societies, leading to differing recommendations and sometimes confusion for both patients and providers.

Decades of Debate: The Evolution of Breast Cancer Screening Guidelines

The history of breast cancer screening is marked by continuous evolution and occasional controversy. Mammography gained widespread acceptance in the 1980s, and by the 1990s, many national guidelines recommended annual screening for women over 40 or 50. Organizations like the American Cancer Society (ACS) and the U.S. Preventive Services Task Force (USPSTF) have long been key players in shaping these recommendations, though their stances have not always aligned perfectly.

The ACS, for instance, generally recommends annual mammograms for women beginning at age 40 and continuing as long as they are in good health. In contrast, the USPSTF advises biennial screening for women aged 50 to 74, suggesting individual decisions for women aged 40-49 based on personal risk and preferences. These disparities highlight the lack of consensus on universal screening strategies, primarily because research has long shown that breast cancer risk can vary greatly from one person to another, influenced by a complex interplay of genetic, biological, and lifestyle factors.

• The Limitations of Age-Based Approaches: Relying solely on age as the primary determinant for screening frequency often overlooks critical nuances. A 40-year-old with a strong family history and dense breasts might face a higher lifetime risk than a 55-year-old with no such factors, yet traditional guidelines might recommend the same or even less frequent screening for the younger, higher-risk individual. This oversight can lead to missed opportunities for early detection in those who need it most.
• The Burden of Overdiagnosis and False Positives: Traditional mass screening also carries the risk of overdiagnosis – detecting cancers that would never have caused symptoms or threatened a woman’s life. While the exact rates are debated, estimates suggest that a significant percentage of screen-detected cancers may fall into this category. Overdiagnosis leads to unnecessary treatment, including surgery, radiation, and chemotherapy, which carry their own physical and psychological tolls. Furthermore, the high rate of false positives – where a mammogram suggests cancer that isn’t present – results in anxiety, additional imaging, and invasive biopsies, adding to healthcare costs and patient distress. It is estimated that nearly 50% of women screened annually for a decade will experience at least one false positive, with approximately 10% undergoing an unnecessary biopsy.

Unpacking the WISDOM Study: Methodology and Design

The WISDOM study was meticulously designed to directly compare the efficacy and safety of traditional annual mammography against a novel screening strategy based on individual risk. Launched in 2016, the study embarked on an ambitious mission to gather robust evidence that could fundamentally alter clinical guidelines.

"These findings should transform clinical guidelines for breast cancer screening and alter clinical practice," asserted Laura J. Esserman, MD, MBA, director of the UCSF Breast Care Center and the study’s first author. "The personalized approach begins with risk assessment, incorporating genetic, biological, and lifestyle factors, which can then guide effective prevention strategies."

• Defining Individual Risk: More Than Just Age: The core innovation of WISDOM lies in its comprehensive risk assessment model. Using well-validated predictive tools, researchers grouped participants into four distinct categories by considering a broad spectrum of risk factors. These included:

  • Age: Still a factor, but not the sole determinant.
  • Genetic Information: Screening for known pathogenic variants like BRCA1 and BRCA2, as well as evaluating polygenic risk scores (PRS) derived from smaller, common DNA changes that collectively influence risk.
  • Lifestyle Factors: Diet, physical activity, alcohol consumption, and body mass index.
  • Health History: Personal history of breast cancer, benign breast disease, and reproductive history.
  • Breast Density: A known independent risk factor, particularly for younger women, which can also obscure tumors on mammograms.

• Tailored Screening Frequencies for Diverse Risk Profiles: Based on this multi-faceted evaluation, participants were assigned to one of four risk-stratified groups, each receiving tailored screening recommendations:

  • Lowest Risk Group (26% of participants): These women were advised to delay screening until age 50 or until an algorithm indicated their risk had naturally reached that of a typical 50-year-old. This represents a significant reduction in screening frequency for a substantial portion of the population, potentially alleviating the burden of unnecessary procedures and anxiety.
  • Average Risk Group (approximately 62% of participants): Advised to undergo screening every two years, aligning with some current guidelines but based on a more precise risk assessment.
  • Elevated Risk Group (8% of participants): Annual mammograms were recommended for this group, ensuring consistent surveillance for those with a higher, but not extreme, risk profile.
  • Highest Risk Group (2% of participants): This cohort received the most intensive screening, advised to receive screening twice a year, alternating between mammography and MRI, regardless of age. MRI is known to be more sensitive for detecting cancers in high-risk women, particularly those with dense breasts or genetic predispositions.

Groundbreaking Results: Efficacy and Patient Acceptance

Crucially, the study demonstrated that this personalized screening approach did not lead to a higher rate of late-stage cancer diagnoses. This finding directly refutes concerns that less frequent screening for lower-risk women might result in delayed detection of aggressive cancers. Instead, the risk-stratified strategy proved equally effective in identifying cancers at an early, treatable stage, while simultaneously optimizing screening intensity.

Patient acceptance of the personalized approach was remarkably high. While the core study involved randomization to either traditional or personalized screening, an observational group was also offered, allowing participants to choose their preferred strategy. Among this group, a compelling 89% opted for risk-based screening, suggesting strong public and patient confidence in the individualized model. This high acceptance rate is vital for the eventual widespread adoption of such guidelines.

• Personalized Prevention for Higher-Risk Women: Beyond just screening, participants identified as having elevated or highest risk also received customized guidance on lowering their chances of developing breast cancer. This support extended beyond mere recommendations, offering practical tools and direct access to specialists. It included:
  • Access to an online decision-making tool focused on breast health.
  • Direct contact with a breast health specialist for personalized consultations.
  • Recommendations for lifestyle changes, such as improving diet and increasing physical activity, which are known to mitigate cancer risk.
  • Discussions about medications, such as tamoxifen or raloxifene, which can help reduce risk in certain high-risk individuals.

"Shifting resources from lower-risk women to higher-risk women is an efficient, effective approach to screening for and preventing breast cancer," noted co-author Jeffrey A. Tice, MD, a UCSF professor of Medicine who specializes in developing and evaluating breast cancer risk assessment tools. This reallocation of resources holds significant implications for healthcare economics, potentially reducing unnecessary costs associated with overscreening while ensuring that diagnostic and preventive efforts are concentrated where they can yield the greatest benefit.

Beyond Family History: The Crucial Role of Genetic Insights

One of the study’s most profound and potentially transformative findings revolved around genetic testing. Since launching in 2016, WISDOM has expanded its enrollment to more than 80,000 women, including women as young as 30, specifically to identify those who may face an increased risk of aggressive early cancers due to inherited genetic variants.

The study revealed that a remarkable 30% of women who tested positive for a genetic variant linked to higher breast cancer risk reported absolutely no family history of the disease. Under current clinical guidelines, which often require a strong family history or specific ancestral criteria to qualify for genetic testing, many of these women would not typically be offered or covered for such crucial screening. This finding underscores a critical blind spot in current practice and advocates for a more universal approach to genetic screening within a comprehensive risk assessment.

In addition to well-known pathogenic variants such as BRCA1 and BRCA2, the study also evaluated smaller DNA changes that, when combined, form a polygenic risk score (PRS). This innovative approach significantly improved the precision of risk predictions and resulted in 12% to 14% of participants being reassigned to a different risk category, demonstrating the power of integrating diverse genetic information.

"This is one of the first studies to offer genetic testing to all women, regardless of family history," stated co-author Allison S. Fiscalini, MPH, of UCSF, director of the Athena Breast Health Network and the WISDOM study. "When used as part of a comprehensive risk assessment, these results could have a real impact on improving the safety and effectiveness of screening and prevention."

Expert Perspectives and Anticipated Reactions

The implications of the WISDOM study are far-reaching and are expected to elicit significant discussion and potential shifts across the medical community, patient advocacy groups, and healthcare policy circles.

• Reshaping Clinical Guidelines and Practice: Medical societies, including the ACS, USPSTF, and the National Comprehensive Cancer Network (NCCN), will likely review their current guidelines in light of these findings. While guideline changes often take time due to the need for replication and consensus, the robust nature of the WISDOM study’s initial phase provides a strong impetus for re-evaluation. Clinicians, particularly primary care physicians and oncologists, will need training and resources to effectively implement risk-based screening protocols, which require a deeper understanding of genetics, risk modeling, and patient communication.
• Empowering Patients with Personalized Prevention: Patient advocacy groups are expected to welcome the findings, as they offer the promise of more tailored, less anxiety-provoking care. For women at lower risk, the prospect of less frequent screening could reduce stress and unnecessary interventions. For those at higher risk, knowing they are receiving optimal, intensive surveillance and personalized prevention strategies could be incredibly empowering. This shift fosters a more proactive and informed patient-provider dialogue about breast health.
• Implications for Insurers and Healthcare Systems: Insurance providers will face decisions regarding coverage for comprehensive risk assessments, including genetic testing and potentially more frequent MRI scans for high-risk individuals. The study’s argument for efficiency and effectiveness suggests that while initial costs for broader genetic testing might rise, long-term savings could be realized through reduced overdiagnosis, fewer unnecessary biopsies, and earlier detection of advanced cancers, which are significantly more expensive to treat. Healthcare systems will need to invest in infrastructure for genetic counseling, risk assessment tools, and coordinated care pathways for personalized screening.

Navigating the Future: Implications for Healthcare Policy and Public Health

The WISDOM study represents a pivotal moment in breast cancer prevention, offering a clear pathway towards a more nuanced, effective, and patient-centered approach. However, successful implementation of personalized screening will require concerted efforts across various sectors.

• Addressing Health Equity: A critical aspect of implementing risk-based screening will be ensuring equitable access to comprehensive risk assessments and genetic testing, regardless of socioeconomic status, geographic location, or ethnic background. Disparities in access to genetic counseling and advanced imaging could exacerbate existing health inequities if not proactively addressed.
• Public Education Campaigns: Widespread public education campaigns will be essential to inform women about the benefits of personalized screening and to help them understand their individual risk profiles. This will require clear, accessible information to alleviate confusion and build trust in the new paradigm.
• The Path Forward: WISDOM 2.0 and Beyond: Researchers are not resting on their laurels. They are continuing to refine risk assessment through the WISDOM 2.0 study, which is actively enrolling participants. The overarching goal of this ongoing research is to better identify women who face an even higher likelihood of developing aggressive breast cancers and to provide them with screening and prevention strategies that are meticulously tailored to their long-term health needs, thereby pushing the boundaries of precision medicine in oncology.

The WISDOM study represents a robust, evidence-based argument for a fundamental shift in breast cancer screening. By embracing individualized risk assessment, the medical community stands to optimize early detection, reduce unnecessary interventions, and ultimately improve the lives of millions of women worldwide. This is not just an incremental improvement; it is a vision for a future where screening is truly personalized, precise, and profoundly effective.

Study Leadership and Funding

The extensive list of co-authors from UCSF includes Laura J. van ‘t Veer, PhD; Maren T. Scheuner MD; Alexander D. Borowsky, MD; Amie M. Blanco, MD; Katherine S. Ross, MS; Barry S. Tong, MS; Diane Heditsian; Susie Brain; Vivian Lee; Kelly Blum, MS; Mi-Ok Kim, PhD; Leah P. Sabacan, MBA; Kirkpatrick B. Fergus, MD; Christina Yau, PhD; Celia Kaplan, DrPH; Suzanne Elder, CFNP; Kelly Adduci, MPH; Jeffrey B. Matthews, PhD; Robert A. Hiatt, MD, PhD; Elad Ziv, MD; and Jeffrey A. Tice, MD.

Additional investigators contributed from UC Los Angeles; UC Irvine; UC San Diego; San Francisco VA Health Care System; Sanford Health in North Dakota; University of Chicago; Diagnostic Center of Miami; University of Alabama; Virginia Commonwealth University; Weill Cornell Medicine in New York; and the Karolinka Institutet in Stockholm.

Study support included generous funding from the Patient Center Outcomes Research Institute, the National Cancer Institute (R01CA237533), and the Breast Cancer Research Foundation, among other sources detailed in the published paper. Conflicts of interest were disclosed, including Dr. Esserman’s role as a medical advisory panel member for Blue Cross Blue Shield and receipt of author fees from UpToDate. Other investigators’ disclosures are available in the study publication.